Delivering more actionable and strategically valuable research, The Business Research Company’s 2026 market reports feature market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights.

Lung Cancer Liquid Biopsy Market Forecast Highlighting Growth From $1.3 Billion To $2.42 Billion

The market for liquid biopsies targeting lung cancer has experienced substantial expansion lately. Projections indicate a rise from $1.12 billion in 2025 to $1.31 billion by 2026, demonstrating a compound annual growth rate of 17.0%. This historical growth trajectory is supported by factors such as a rising prevalence of lung cancer, the inherent challenges associated with traditional tissue biopsy methods, progress made in molecular diagnostic techniques, the accessibility of technologies for detecting circulating biomarkers, and a surge in research endeavors within the field of oncology.

The market for liquid biopsies in lung cancer diagnosis is poised for substantial expansion in the coming years, projected to reach $2.42 billion by 2030 with a compound annual growth rate (CAGR) of 16.7%. This upward trajectory is fueled by several key factors, including a heightened demand for personalized cancer treatment strategies, the broadening scope of liquid biopsy applications in clinical settings, an increasing reliance on companion diagnostics, the growing integration of artificial intelligence for data analysis, and a stronger emphasis on early cancer detection initiatives. Furthermore, significant trends shaping this market during the forecast period involve a greater acceptance of non-invasive diagnostic methods, a rise in the utilization of next-generation sequencing (NGS) for liquid biopsy testing, a surging need for early cancer identification, the continuous development of personalized diagnostic tools for oncology, and improved integration of bioinformatics platforms.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24593&type=smp

Lung Cancer Liquid Biopsy Market Expansion Supported By Key Demand Factors

The anticipated rise in lung cancer cases is poised to be a significant catalyst for the expansion of the lung cancer liquid biopsy market. This malignancy, defined by the aberrant proliferation of cellular material within the pulmonary tissues and frequently linked to tobacco consumption and exposure to harmful environmental agents, is experiencing a surge primarily attributed to persistent tobacco usage. The carcinogenic elements inhaled through smoking initiate aberrant cellular development, thereby fueling the escalating rates of lung cancer. Liquid biopsies for lung cancer offer a crucial advantage by identifying specific genetic alterations associated with cancer and circulating tumor DNA from a simple blood draw, thereby facilitating prompt diagnosis, guiding therapeutic choices, and enabling the tracking of disease advancement or the efficacy of treatments. For illustration, recent data from the American Cancer Society, a research organization based in the United States, projected that in 2023, approximately 238,340 diagnoses of lung cancer would be made, with 117,550 among men and 120,790 among women, and an estimated 127,070 fatalities from the disease. Consequently, the growing prevalence of lung cancer is directly stimulating the market for liquid biopsy solutions.

Lung Cancer Liquid Biopsy Market Segment Outlook: Which Categories Are Expanding The Fastest?

The lung cancer liquid biopsy market covered in this report is segmented –

1) By Product: Instruments, Consumables, Kits And Reagents, Software And Services

2) By Technology: Multi-Gene-Parallel Analysis (Ngs), Single-Gene Analysis (PCR Microarrays)

3) By Biomarker: Cell-Free Deoxyribonucleic Acid, Circulating Tumor Deoxyribonucleic Acid, Extracellular Vesicles, Circulating Tumor Cells, Other Biomarkers

4) By Clinical Application: Therapy Selection, Treatment Monitoring, Early Cancer Screening, Recurrence Monitoring, Other Applications

5) By End User: Diagnostics And Imaging Centres, Hospitals, Academics And Research Centers, Other End Users

Subsegments:

1) By Instruments: PCR Instruments, Microarray Instruments, Next-Generation Sequencing (NGS) Instruments

2) By Consumables Kits And Reagents: Sample Collection Kits, Amplification Reagents, Sequencing Reagents

3) By Software And Services: Data Analysis Software, Cloud-Based Services, Bioinformatics Tools

Lung Cancer Liquid Biopsy Market Growth Trends Influencing Competitive Dynamics

Companies leading the lung cancer liquid biopsy sector are prioritizing innovation in technologies like blood-based screening for lung cancer to bolster early detection, refine diagnostic precision, and facilitate unobtrusive, continuous tracking of disease advancement and therapeutic effectiveness. This non-invasive method of screening for lung cancer involves examining biological markers within the blood to identify the disease in its nascent stages. As an illustration, DELFI Diagnostics Inc., a US biotechnology firm, introduced FirstLook Lung in October 2023, a liquid biopsy blood test engineered for the early identification of lung cancer. This test utilizes fragmentomics, achieving high sensitivity in detecting early lung cancer and boasting a 99.8% negative predictive value, positioning it as a practical and readily available initial assessment for individuals at risk, with the aim of enhancing early detection rates, promoting greater screening participation, and guiding imaging resources toward those most likely to gain from them.

Lung Cancer Liquid Biopsy Market Key Companies And Competitive Benchmarking

Major companies operating in the lung cancer liquid biopsy market are F. Hoffmann-La Roche Ltd, Thermo Fisher Scientific Inc., Biocept Inc., Agilent Technologies Inc., Eurofins Scientific, Illumina Inc., Sysmex Corporation, Bio-Rad Laboratories Inc., QIAGEN N.V., Natera Inc., Myriad Genetics Inc., NeoGenomics Laboratories Inc., Guardant Health Inc., Exosome Diagnostics Inc., Menarini Silicon Biosystems S.p.A., Inivata Ltd, Lucence Diagnostics Pte Ltd, LungLife AI Inc., Biodesix Inc., Oncocyte Corporation

Access The Complete Lung Cancer Liquid Biopsy Market Report:

https://www.thebusinessresearchcompany.com/report/lung-cancer-liquid-biopsy-global-market-report

Lung Cancer Liquid Biopsy Market Geographic Analysis: Where Is Demand Growing The Fastest?

North Americawas the largest region in the lung cancer liquid biopsy market in 2025. Asia-Pacificis expected to be the fastest-growing region in the forecast period. The regions covered in the lung cancer liquid biopsy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model